XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING
 3 Months Ended
Mar. 31, 2024
Restructuring Charges [Abstract]  
RESTRUCTURING RESTRUCTURING
2023 Restructuring Plan

In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities. Consistent with our prioritization and efficiency goals communicated earlier this year, BMS continues to execute on strategic productivity initiatives through portfolio prioritization and management of our operating costs. Total expected restructuring costs under the 2023 Restructuring Plan to be incurred through 2026 are approximately $1.5 billion. These costs consist primarily of employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

Celgene and Other Acquisition Plans

Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). The remaining charges of approximately $500 million consist primarily of employee termination costs, IT system integration costs and to a lesser extent site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended March 31,
Dollars in millions20242023
2023 Restructuring Plan$68 $61 
Celgene and Other Acquisition Plans244 74 
Total charges$312 $135 
Employee termination costs$217 $65 
Other termination costs3 2 
Provision for restructuring220 67 
Integration expenses71 67 
Accelerated depreciation14 1 
Asset impairments2 — 
Other shutdown costs5 — 
Total charges$312 $135 
Cost of products sold$14 $1 
Marketing, selling and administrative6 — 
Research and development1 — 
Other (income)/expense, net291 134 
Total charges$312 $135 

The following summarizes the charges and spending related to restructuring plan activities:
Three Months Ended March 31,
Dollars in millions20242023
Beginning balance $188 $47 
Provision for restructuring220 67 
Foreign currency translation and other(2)2 
Payments(97)(17)
Ending balance$309 $99